Answers are grounded in this paper and cite their sources.
We suggest assessing ADA2 activity along with genetic analysis because there are patients with one ADA2 mutation and absent enzyme activity. Our data suggest a possible genotype-phenotype correlation in which dimerization domain mutations are associated with PAN-like phenotype, and catalytic domain mutations are associated with hematological manifestations.
No takes yet. Share an insight, caveat, or question.
Özen et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: